Clinical Trials
- Liver
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)
- Ages18 years - 75 years
- GenderBoth
- Liver
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- Ages18 years - 75 years
- GenderBoth
- Liver
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM)
- Ages18 years and older
- GenderBoth
- Liver
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
- Ages18 years - 75 years
- GenderBoth
- Liver
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)
- Ages18 years and older
- GenderBoth
- Liver
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)
- Ages18 years - 75 years
- GenderBoth
- Liver
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)
- Ages18 years - 75 years
- GenderBoth
- Hepatitis, Liver
Digoxin In Alcohol Associated Hepatitis
- Ages21 years - 65 years
- GenderBoth
- Liver, Genetics
Genetic Studies of Polycystic Livers
- Ages18 years and older
- GenderBoth